Jbf Capital, Inc. Argenx Se Transaction History

Jbf Capital, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 13, 2018	SELL	$75.5 - $96.63 $1.58 Million - $2.03 Million	-20,990 Closed	0 $0
Q2 2018 Aug 09, 2018	SELL	$74.84 - $100.16 $374,200 - $500,800	-5,000 Reduced 19.24%	20,990 $1.74 Million
Q1 2018 May 11, 2018	BUY	$56.95 - $85.19 $1.48 Million - $2.21 Million	25,990 New	25,990 $2.09 Million

399

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $33.5B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Jbf Capital, Inc., based on Form 13F filings with the SEC.

Stay updated on Jbf Capital, Inc. with notifications on news.